Evidence map›Paper›PMID 19376888›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2009

Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction.

G S Supinski, J Vanags, L A Callahan

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 66 citations in OpenAlex.

  1. Forgotten muscle: diaphragm and sudden infant death syndrome.World journal of pediatrics : WJP · 2026
    Article
  2. Review
  3. The proteasome regulates body weight and systemic nutrient metabolism during fasting.American journal of physiology. Endocrinology and metabolism · 2023
    Article
  4. Exploring the Muscle Metabolomics in the Mouse Model of Sepsis-Induced Acquired Weakness.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. MitoTEMPOL, a mitochondrial targeted antioxidant, prevents sepsis-induced diaphragm dysfunction.American journal of physiology. Lung cellular and molecular physiology · 2020
    Article
  10. Taurine administration ablates sepsis induced diaphragm weakness.Respiratory physiology & neurobiology · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Cancer cachexia-when proteasomal inhibition is not enough.Journal of cachexia, sarcopenia and muscle · 2016
    Article
  20. Calcium-dependent phospholipase A2 modulates infection-induced diaphragm dysfunction.American journal of physiology. Lung cellular and molecular physiology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

G S SupinskiDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky, Lexington, KY 40536-0284, USA. gsupi2@email.uky.edu
J Vanags
L A Callahan
University of Kentucky · US

Funding

MAPK/PKR Modulation of Diaphragm WeaknessR01HL081525 · NHLBI · UNIVERSITY OF KENTUCKY · PI SUPINSKI, GERALD S. · 2006 to 2010
$1.8M
FREE RADICALS AND MUSCLE DYSFUNCTION IN HEART FAILURER01HL063698 · NHLBI · UNIVERSITY OF ROCHESTER · PI SUPINSKI, GERALD S. · 2000 to 2005
$1.6M
Oxidant Mediated Diaphragm Dysfunction in DiabetesR01HL080609 · NHLBI · UNIVERSITY OF KENTUCKY · PI CALLAHAN, LEIGH A · 2006 to 2009
$1.4M
Caspase Mediated Diaphragmatic DysfunctionR01HL080429 · NHLBI · UNIVERSITY OF KENTUCKY · PI SUPINSKI, GERALD S. · 2006 to 2009
$1.4M
Diaphragm Mitochondrial Alterations in SepsisR01HL069821 · NHLBI · UNIVERSITY OF ROCHESTER · PI CALLAHAN, LEIGH A · 2001 to 2004
$1.3M
NHLBI NIH HHS HL-63698NHLBI NIH HHS HL-69821NHLBI NIH HHS HL-80429NHLBI NIH HHS HL-80609NHLBI NIH HHS HL-81525NHLBI NIH HHS R01 HL080429NHLBI NIH HHS R01 HL081525
6 · The paper itself

Abstract

Infections produce severe respiratory muscle dysfunction. It is known that the proteasome proteolytic system is activated in skeletal muscle in sepsis, and it has been postulated that this degradative pathway is responsible for inducing skeletal muscle weakness and wasting. The objective of this study was to determine if administration of proteasomal inhibitors (MG132, epoxomicin, bortezomib) can prevent sepsis-induced diaphragm weakness. Rats were given either 1) saline (0.5 ml ip), 2) endotoxin (12 mg/kg ip), 3) endotoxin plus MG132 (2.5 mg/kg), 4) endotoxin plus epoxomicin (1 micromol/kg), or 5) endotoxin plus bortezomib (0.05 mg/kg). Animals were killed either 48 or 96 h after injections, and assessments were made of diaphragm proteolysis, force-frequency relationships, mass, protein content, and caspase activation. Endotoxin increased proteolysis (P <0.001). MG132, epoxomicin, and bortezomib each prevented the endotoxin-induced increase in proteolysis (P <0.01). Endotoxin induced severe reductions in diaphragm force generation by 48 h (P <0.01); none of the proteasomal inhibitors prevented loss of force. Endotoxin induced significant reductions in diaphragm mass and protein content by 96 h (P <0.01); neither MG132 nor epoxomicin prevented loss of mass or protein, but bortezomib attenuated the reduction in protein content (P <0.05). Endotoxin increased diaphragm caspase-3 activity (P <0.01); caspase-3 activity remained high when either MG132, epoxomicin, or bortezomib were given. These data suggest proteasomal inhibitors are not an adequate treatment to prevent endotoxin-induced diaphragmatic dysfunction.

Indexed as

Proteasome InhibitorsAnimalsAtrophyBoronic AcidsBortezomibCaspase 3Cysteine Proteinase InhibitorsDiaphragmEndotoxemiaEnzyme ActivationLeupeptinsMaleMuscle ContractionMuscle WeaknessOligopeptidesOrgan Sizebenzyloxycarbonylleucyl-leucyl-leucine aldehydeBoronic AcidsBortezomibCasp3 protein, ratCaspase 3Cysteine Proteinase InhibitorsepoxomicinLeupeptinsOligopeptidesProtease InhibitorsProteasome Endopeptidase ComplexProteasome InhibitorsPyrazinesTyrosine

Identifiers

PMID19376888
PMCPMC2692801
OpenAlexW2130903085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.